book chapter
Manganese is essential for physiological functions in trace amounts, but chronic exposure, particularly in occupational settings like mining, can lead to manganism. While manganism presents symptoms similar to Parkinson's disease, such as bradykinesia and rigidity, its underlying pathophysiology is distinct. Manganism primarily affects the globus pallidus and striatum, differing from Parkinson's disease in dopaminergic dysfunction and neuronal degeneration. A key distinction is manganism's poor response to levodopa, necessitating a differential diagnosis and specific management strategies. This work aims to clarify manganese neurotoxicity, its clinical features, diagnostic difficulties, and treatment options, considering environmental health and occupational safety.
Distinguishing manganism from Parkinson's disease is crucial for accurate diagnosis and effective treatment, as their underlying mechanisms and responses to medication differ significantly. This understanding can improve patient outcomes and inform public health policies regarding environmental and occupational manganese exposure.
The insights into diagnostic challenges and therapeutic approaches for manganism could inform the development of improved diagnostic tools or targeted treatment protocols. Furthermore, understanding the implications for environmental health and occupational safety could lead to enhanced safety guidelines and preventative measures, benefiting industries with manganese exposure. This appears to be early-stage research informing clinical and policy development.
AI-generated from the published abstract. Always read the original work before citing.
Manganese is needed in trace amounts for physiological functions, such as enzymatic activity. However, chronic exposure to manganese, which has been reported in occupational settings such as mining, can lead to manganism. While Manganism shares similar symptoms (e.g bradykinesia, rigidity, and postural instability) with Parkinson's disease (PD), its pathophysiology is distinct from PD. Contrary to PD, globus pallidus and striatum are the primary damaged structures in manganism. Differences in dopaminergic dysfunction, and neuronal degeneration between the two conditions have been reported. Importantly, manganism often shows poor response to levodopa, underscoring the need for differential diagnosis and tailored management strategies. This write-up points out the basis of manganese neurotoxicity, its clinical manifestations, diagnostic challenges, and therapeutic approaches, while also examining the implications for environmental health and occupational safety. the chapter aims to enhance understanding of manganese and Parkinsonism.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4018/979-8-2600-1403-5.ch008
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
